Item Type | Name |
Concept
|
Hematopoietic Stem Cell Transplantation
|
Academic Article
|
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
|
Academic Article
|
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
|
Academic Article
|
Autologous and allogeneic transplantation for aggressive NHL.
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
Academic Article
|
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
Academic Article
|
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
Academic Article
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
Academic Article
|
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
Academic Article
|
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
|
Academic Article
|
Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation.
|
Academic Article
|
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
|
Academic Article
|
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants.
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity.
|
Academic Article
|
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
|
Academic Article
|
Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.
|
Academic Article
|
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
|
Academic Article
|
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.
|
Academic Article
|
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
|
Academic Article
|
Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients.
|
Academic Article
|
Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia.
|
Academic Article
|
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
|
Academic Article
|
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
|
Academic Article
|
Nonmyeloablative conditioning for relapsed follicular lymphoma.
|
Academic Article
|
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.
|
Academic Article
|
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
|
Academic Article
|
Stem cell transplantation in follicular lymphoma: progress at last?
|
Academic Article
|
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
|
Academic Article
|
Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.
|
Academic Article
|
Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma.
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
Academic Article
|
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
|
Academic Article
|
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
|
Academic Article
|
Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned.
|
Academic Article
|
Toxicity of single daily dose gentamicin in stem cell transplantation.
|
Academic Article
|
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
|
Academic Article
|
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
|
Academic Article
|
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.
|
Academic Article
|
Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
|
Academic Article
|
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.
|
Academic Article
|
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
|
Academic Article
|
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
|
Academic Article
|
A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.
|
Academic Article
|
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
|
Academic Article
|
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
|
Academic Article
|
Hematopoietic stem cell transplantation for myelofibrosis.
|
Academic Article
|
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
|
Academic Article
|
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.
|
Academic Article
|
Therapeutic drug monitoring: a way to improve long-term immunological balance?
|
Academic Article
|
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
|
Academic Article
|
Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments.
|
Academic Article
|
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.
|
Academic Article
|
Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies.
|
Academic Article
|
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
|
Academic Article
|
High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
|
Academic Article
|
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
|
Academic Article
|
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
|
Academic Article
|
Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation.
|
Academic Article
|
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
|
Academic Article
|
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
|
Academic Article
|
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.
|
Academic Article
|
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
|
Academic Article
|
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities.
|
Academic Article
|
Allogeneic blood stem cell transplantation in advanced hematologic cancers.
|
Academic Article
|
Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications.
|
Academic Article
|
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
|
Academic Article
|
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.
|
Academic Article
|
Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma.
|
Academic Article
|
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
|
Academic Article
|
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
|
Academic Article
|
Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue.
|
Academic Article
|
Primary mediastinal B-cell lymphoma: a review of pathology and management.
|
Academic Article
|
Studies of decitabine with allogeneic progenitor cell transplantation.
|
Academic Article
|
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.
|
Academic Article
|
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma.
|
Academic Article
|
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
|
Academic Article
|
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
|
Academic Article
|
To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?
|
Academic Article
|
A strategy to reduce donor-specific HLA Abs before allogeneic transplantation.
|
Academic Article
|
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
|
Academic Article
|
Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy.
|
Academic Article
|
Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions.
|
Academic Article
|
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
|
Academic Article
|
Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
|
Academic Article
|
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
|
Academic Article
|
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
|
Academic Article
|
The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.
|
Academic Article
|
Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
|
Academic Article
|
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Superiority of reduced-intensity conditioning for Hodgkin's lymphoma.
|
Academic Article
|
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.
|
Academic Article
|
Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection.
|
Academic Article
|
Alemtuzumab in allogeneic hematopoetic stem cell transplantation.
|
Academic Article
|
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
|
Academic Article
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
|
Academic Article
|
Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
|
Academic Article
|
Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant.
|
Academic Article
|
Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions.
|
Academic Article
|
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.
|
Academic Article
|
Stem-cell transplantation for sickle cell disease.
|
Academic Article
|
Toxicity of high dose BCNU: how much is too much?
|
Academic Article
|
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.
|
Academic Article
|
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
|
Academic Article
|
Reduced-intensity and nonmyeloablative conditioning regimens.
|
Academic Article
|
The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma.
|
Academic Article
|
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
|
Academic Article
|
Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
|
Academic Article
|
Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease.
|
Academic Article
|
Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.
|
Academic Article
|
Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects?
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
Academic Article
|
A new "age" for high dose therapy and autologous stem cell transplant.
|
Academic Article
|
Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum.
|
Academic Article
|
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
|
Academic Article
|
DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center.
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
Academic Article
|
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
|
Academic Article
|
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.
|
Academic Article
|
Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.
|
Academic Article
|
Haploidentical cord transplantation-The best of both worlds.
|
Academic Article
|
Second allogeneic transplantation: ever? never? or sometimes.
|
Academic Article
|
Clofarabine as a bridge to hematopoietic stem cell transplant.
|
Academic Article
|
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy.
|
Academic Article
|
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
|
Academic Article
|
Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors.
|
Academic Article
|
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.
|
Academic Article
|
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
|
Academic Article
|
A renaissance for autologous transplantation in follicular lymphoma?
|
Academic Article
|
Colonization With Levofloxacin-resistant Extended-spectrum ß-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
Academic Article
|
Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients.
|
Academic Article
|
Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cells-a single-institution experience.
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
Academic Article
|
Donor graft genotypes versus leukemia.
|
Academic Article
|
Tocilizumab, in search for a role in acute GVHD.
|
Academic Article
|
Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients.
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies.
|
Academic Article
|
Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts?
|
Academic Article
|
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
|
Academic Article
|
Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
|
Academic Article
|
Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?
|
Academic Article
|
Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation.
|
Academic Article
|
Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients.
|
Academic Article
|
MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
|
Academic Article
|
Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations.
|
Academic Article
|
Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes.
|
Academic Article
|
Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
|
Academic Article
|
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.
|
Academic Article
|
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy.
|
Academic Article
|
Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation.
|
Academic Article
|
Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
HIV-1 remission and possible cure in a woman after haplo-cord blood transplant.
|
Academic Article
|
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD).
|
Academic Article
|
Immune reconstitution inflammatory syndrome in a patient with M.haemophilum infection after allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
|
Academic Article
|
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).
|
Academic Article
|
High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role?
|